# The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects

> **NCT02372630** · PHASE4 · COMPLETED · sponsor: **University at Buffalo** · enrollment: 40 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Linagliptin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02372630
- **Lead sponsor:** University at Buffalo
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-23
- **Primary completion:** 2018-02-01
- **Final completion:** 2018-05-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2023-02-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02372630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02372630, "The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02372630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*